{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:12Z","timestamp":1791563112797,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Polyclonal rabbit antithymocyte globulins (ATGs) are commonly used in organ transplantation as induction. Anti-<jats:italic toggle=\"yes\">N<\/jats:italic>-glycolylneuraminic acid carbohydrate antibodies which develop in response to rabbit carbohydrate antigens might lead to unwanted systemic inflammation. LIS1, the first new generation of antilymphocyte globulins (ALGs) derived from double knockout swine, lacking carbohydrate xenoantigens was already tested in nonhuman primates and rodent models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This open-label, single-site, dose escalation, first-in-human, phase 1 study evaluated the safety, T cell depletion, pharmacokinetics, and pharmacodynamics of LIS1. In an ascending dose cohort (n\u2005=\u20055), a primary kidney transplant recipient at low immunologic risk (panel reactive antibody [PRA]\u2005&lt;\u200520%), received LIS1 for 5 d at either 0.6, 1, 3, 6, or 8\u2009mg\/kg. After each patient completed treatment, the data safety monitoring board approved respective dose escalation. In the therapeutic dose cohort (n\u2005=\u20055) in patients with PRA &lt;50% without donor specific antibodies, 2 patients received 8\u2009mg\/kg and 3 patients 10\u2009mg\/kg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>CD3<jats:sup>+<\/jats:sup> T cell depletion &lt;100\/mm<jats:sup>3<\/jats:sup> at day 2 was observed in all patients who received 6, 8, and 10\u2009mg\/kg of LIS1. The terminal half-life of LIS1 was 33.7 d with linearity in its disposition. Lymphocyte repopulation was fast and pretransplant lymphocyte subpopulation counts recovered within 2\u20134\u2009wk. LIS1 was well tolerated, neither cytokine release syndrome nor severe thrombocytopenia or leukopenia were noticed. Antibodies to LIS1 were not detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In this first-in-human trial, genome-edited swine-derived polyclonal LIS1 ALG was well tolerated, did not elicit antidrug antibodies, and caused time-limited T cell depletion in low- and medium-risk kidney transplant recipients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004967","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:01:08Z","timestamp":1709182868000},"page":"e139-e147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation"],"prefix":"10.1097","volume":"108","author":[{"given":"Ondrej","family":"Viklicky","sequence":"first","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janka","family":"Slatinska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Janousek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Rousse","sequence":"additional","affiliation":[{"name":"Xenothera, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Joseph","family":"Royer","sequence":"additional","affiliation":[{"name":"Xenothera, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"Toutain","sequence":"additional","affiliation":[{"name":"Comparative Biomedical Sciences, The Royal Veterinary College, London, United Kingdom."},{"name":"INTHERES, Universit\u00e9 de Toulouse, INRAE, ENVT, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzi","sequence":"additional","affiliation":[{"name":"Transplantation Immunology Unit, Padua University Hospital, Padova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Galli","sequence":"additional","affiliation":[{"name":"Avantea, Laboratory of Reproductive Technologies, Cremona, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Evanno","sequence":"additional","affiliation":[{"name":"Xenothera, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Duvaux","sequence":"additional","affiliation":[{"name":"Xenothera, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Bach","sequence":"additional","affiliation":[{"name":"Oniris, INRAE, IECM, USC 1383, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Soulillou","sequence":"additional","affiliation":[{"name":"Institut de Transplantation Urologie N\u00e9phrologie (ITUN), CHU Nantes, Nantes, France."},{"name":"Nantes Universit\u00e9, INSERM UMR1064, Center for Research in Transplantation and Translational Immunology, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Giral","sequence":"additional","affiliation":[{"name":"Institut de Transplantation Urologie N\u00e9phrologie (ITUN), CHU Nantes, Nantes, France."},{"name":"Nantes Universit\u00e9, INSERM UMR1064, Center for Research in Transplantation and Translational Immunology, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Vanhove","sequence":"additional","affiliation":[{"name":"Xenothera, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Blancho","sequence":"additional","affiliation":[{"name":"Institut de Transplantation Urologie N\u00e9phrologie (ITUN), CHU Nantes, Nantes, France."},{"name":"Nantes Universit\u00e9, INSERM UMR1064, Center for Research in Transplantation and Translational Immunology, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.transproceed.2010.04.019","article-title":"A review of the evidence for use of thymoglobulin induction in renal transplantation.","volume":"42","author":"Gaber","year":"2010","journal-title":"Transplant Proc"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-20250604","first-page":"1601","article-title":"Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.","volume":"32","author":"Bamoulid","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.TP.0000116442.81259.60","article-title":"Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study.","volume":"77","author":"Ducloux","year":"2004","journal-title":"Transplantation"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.transproceed.2007.01.024","article-title":"Thymoglobulin and rate of infectious complications after transplantation.","volume":"39","author":"Clesca","year":"2007","journal-title":"Transplant Proc"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-0012.2006.00519.x","article-title":"Infectious complications after kidney transplantation: current epidemiology and associated risk factors.","volume":"20","author":"Alangaden","year":"2006","journal-title":"Clin Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1097\/TP.0000000000001686","article-title":"Anti-Gal and Anti-Neu5Gc responses in nonimmunosuppressed patients after treatment with rabbit antithymocyte polyclonal IgGs.","volume":"101","author":"Salama","year":"2017","journal-title":"Transplantation"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1172\/JCI82267","article-title":"Rabbit antithymocyte globulin\u2013induced serum sickness disease and human kidney graft survival.","volume":"125","author":"Couvrat-Desvergnes","year":"2015","journal-title":"J Clin Invest"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"16036","DOI":"10.1073\/pnas.1902902116","article-title":"Human species-specific loss of CMP- N -acetylneuraminic acid hydroxylase enhances atherosclerosis via intrinsic and extrinsic mechanisms.","volume":"116","author":"Kawanishi","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/glycob\/cwac048","article-title":"N-glycolylated carbohydrates in nature.","volume":"32","author":"Awofiranye","year":"2022","journal-title":"Glycobiology"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3389\/fimmu.2020.00834","article-title":"Challenging the role of diet-induced anti-Neu5Gc Antibodies in Human Pathologies.","volume":"11","author":"Soulillou","year":"2020","journal-title":"Front Immunol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/eji.202049072","article-title":"High neutralizing potency of swine glyco\u2010humanized polyclonal antibodies against SARS\u2010CoV\u20102.","volume":"51","author":"Vanhove","year":"2021","journal-title":"Eur J Immunol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1137629","DOI":"10.3389\/fimmu.2023.1137629","article-title":"LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation.","volume":"14","author":"Rousse","year":"2023","journal-title":"Front Immunol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"e0123721","DOI":"10.1128\/AAC.01237-21","article-title":"Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study.","volume":"65","author":"Gaborit","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/TP.0000000000003047","article-title":"In vivo analysis of human immune responses in immunodeficient rats.","volume":"104","author":"M\u00e9noret","year":"2020","journal-title":"Transplantation"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.transproceed.2004.12.200","article-title":"Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients.","volume":"37","author":"Esposito","year":"2005","journal-title":"Transplant Proc"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.trre.2017.02.004","article-title":"Antithymocyte globulins in renal transplantation\u2014from lymphocyte depletion to lymphocyte activation: the doubled-edged sword.","volume":"31","author":"Bamoulid","year":"2017","journal-title":"Transplant Rev"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1086\/597089","article-title":"Infectious complications of antilymphocyte therapies in solid organ transplantation.","volume":"48","author":"Issa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"e13257","DOI":"10.1111\/tid.13257","article-title":"Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab.","volume":"22","author":"Pham","year":"2020","journal-title":"Transpl Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:06:06Z","timestamp":1749060366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004967","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}